Drug Information

Drug General Information
Drug ID
D0C7WO
Former ID
DPR000003
Drug Name
1192U90
Synonyms
LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide
Drug Type
Small molecular drug
Indication Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] Phase 1 [534252]
Schizophrenia [ICD9: 295; ICD10:F20] Terminated [536463]
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL
Formula
C22H27N5OS
Canonical SMILES
C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2N)C3=NSC4=CC=CC=C43
InChI
1S/C22H27N5OS/c23-19-9-3-1-7-17(19)22(28)24-11-5-6-12-26-13-15-27(16-14-26)21-18-8-2-4-10-20(18)29-25-21/h1-4,7-10H,5-6,11-16,23H2,(H,24,28)
InChIKey
GMDXHLCLNHCEIC-UHFFFAOYSA-N
CAS Number
CAS 155289-31-9
PubChem Compound ID
127912
PubChem Substance ID
10241898, 14904169, 29307084, 48105199, 48404488, 49875314, 57342373, 77091046, 85210089, 104366917, 127973779, 134339491, 135083149, 136351148, 234786072, 242100538
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Antagonist [536463]
5-hydroxytryptamine 1A receptor Target Info Agonist [536463]
5-hydroxytryptamine 2A receptor Target Info Antagonist [536463]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholismhsa04024:cAMP signaling pathway
Serotonergic synapsehsa04020:Calcium signaling pathway
Serotonergic synapse
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
Reactome Dopamine receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (q) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic NeuronsWP722:Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Gastrin-CREB signalling pathway via PKC and MAPK
GPCRs, Other
References
Ref 5342521192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology. 1996 Sep;15(3):231-42.
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.